Clinical Trials Browser

Osteosarcoma

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms

Stomach Neoplasms

Neoplasm Metastasis

Advanced Breast Cancer

Breast Cancer Metastatic

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Brain Neoplasms, Glioblastoma, Neoplasm Metastasis, Meningeal Carcinomatosis

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms

Pancreatic Neoplasms, Colorectal Neoplasms

Colorectal Neoplasms

Salivary Gland Neoplasms

Ovarian Neoplasms, Recurrence

Neoplasm Metastasis, Neoplasms

Stomach Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms

Neoplasm Metastasis

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Breast Cancer With Brain Metastasis

Breast Neoplasms

HER2-mutant Non-Small Cell Lung Cancer

Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Meningeal Carcinomatosis

HER2-low Hormone Receptor Positive Breast Cancer

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Neoplasm Metastasis

Breast Neoplasms

HER2-negative Breast Cancer

Adenocarcinoma, Stomach Neoplasms

Gastric Adenocarcinoma

Esophageal Neoplasms, Stomach Neoplasms, Neoplasm, Residual

Triple Negative Breast Neoplasms

Breast Neoplasms

Clinical Trials

Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma

TRANSCENDER

TUXEDO-4

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

PONTIAC

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

DG-03

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

HERCULES

Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer

ELPIS

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

STORM

DPT02

DESTINY-CRC02

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

TROY

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

ANISE

DESTINY-LUNG02

Scalp Cooling in MBC

ADAPTHER2-IV

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

HUDSON

TRADE DXd

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

DPT01

HER2CLIMB-04

ALTER

THUNDER

ARIADNE

DL-05

DEMETHER

DESTINY-Breast01

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

DEBBRAH

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

DAISY

DESTINY-Lung01

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer

ORIENTA

DG-06

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

DECIPHER

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

TUXEDO-1